Boston scientific announces agreement to acquire apollo endosurgery, inc.

Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures marlborough, mass. , nov. 29, 2022 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has entered into a definitive agreement to acquire apollo endosurgery, inc. (nasdaq: apen) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1 the apollo endosurgery product portfolio includes devices used during endoluminal surgery (els) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity.
APEN Ratings Summary
APEN Quant Ranking